The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Open accessThe DOI matches its Crossref record; 452 of the 457 references it cites were found in a registry or an index.
Abstract
The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs. This hypothesis was based on the discovery that fibril-free synthetic preparations of AβOs were potent CNS neurotoxins that rapidly inhibited long-term potentiation and, with time, caused selective nerve cell death (Lambert et al., 1998). The mechanism was attributed to disrupted signaling involving the tyrosine-protein kinase Fyn, mediated by an unknown toxin receptor. Over 4,000 articles concerning AβOs have been published since then, including more than 400 reviews. AβOs have been shown to accumulate in an AD-dependent manner in human and animal model brain tissue and, experimentally, to impair learning and memory and instigate major facets of AD neuropathology, including tau pathology, synapse deterioration and loss, inflammation, and oxidative damage. As reviewed by Hayden and Teplow in 2013, the AβO hypothesis "has all but supplanted the amyloid cascade." Despite the emerging understanding of the role played by AβOs in AD pathogenesis, AβOs have not yet received the clinical attention given to amyloid plaques, which have been at the core of major attempts at therapeutics and diagnostics but are no longer regarded as the most pathogenic form of Aβ. However, if the momentum of AβO research continues, particularly efforts to elucidate key aspects of structure, a clear path to a successful disease modifying therapy can be envisioned. Ensuring that lessons learned from recent, late-stage clinical failures are applied appropriately throughout therapeutic development will further enable the likelihood of a successful therapy in the near-term.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig.1 AβOs, not Aβ monomers or fibrils, instigate the neuron damage leading to dementia. Following cleavage from the membrane, Aβ peptides aggregate to form AβOs, some of which further aggregate to fibrils and some of which instigate the neuron damage leading to dementia. Reprinted with Jannis Productions permissions from the “Progress Report on Alzheimer’s Disease 2004-2005” (ed. AB Rodgers), NIH Publication Number: 05-5724. Digital images produced by Stacy Jannis and Rebekah Fredenburg of Jannis Productions [455].](https://figures.cochat.ai/paper-figures/f6b42a17775e4881b942c99d83b0c0fa/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-1.jpg)
![Fig.2 AβOs instigate multiple facets of AD-neuropathology. Observed in various culture and animal models. Reprinted by permission from Springer Nature: Acta Neuropathol, 129(2): 183-206, “Amyloid beta oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis” by Viola KL and Klein WL. Copyright 2015 Springer Nature [200].](https://figures.cochat.ai/paper-figures/4c12da5f31934b84a9263cc86d9b1ffd/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-2.jpg)

![Fig.4 AβOs can be divided into two classes based on their temporal, spatial, and structural relationships to amyloid plaques as well as their ability to cause memory dysfunction. Type 1 AβOs (aka “peak 1” or HMW) are thought to be associated with memory impairment, while type 2 AβOs (aka “peak 2” or LMW) are not. Only type 2 AβOs are associated with amyloid plaques. Reprinted from “Quaternary Structure Defines a Large Class of Amyloid-beta Oligomers Neutralized by Sequestration” by Liu P, Reed MN, Kotilinek LA, Grant MK, Forster CL, Qiang W, Shapiro SL, Reichl JH, Chiang AC, Jankowsky JL, Wilmot CM, Cleary JP, Zahs KR, and Ashe KH. This was published in Cell Rep, 2015, 11(11): 1760-1771, under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/ [119].](https://figures.cochat.ai/paper-figures/c5448ccd6aa14c24a04007d7a6986c4e/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-4.jpg)
![Fig.5 Only high-molecular weight AβOs are capable of binding cultured hippocampal neurons. Synthetic AβOs were divided into high and low molecular weight populations using 50 kDa molecular weight cutoff ultrafiltration (A-B) or size exclusion chromatography (D-F) and incubated with cultured hippocampal neurons. Only high-molecular weight AβOs bind neurons (A, E); no binding of low-molecular weight AβOs was evident (B, F). Scale bar = 40μm. Reprinted from “Synaptic targeting by Alzheimer’s-related amyloid beta oligomers” by Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, and Klein WL. This was published in J Neurosci, 2004, 24(45): 10191-10200, copyright 2004; permission conveyed through Copyright Clearance Center, Inc. [16].](https://figures.cochat.ai/paper-figures/16de889766c74140a8a5dc196a8cc4d2/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-5.jpg)
![Fig.6 PrPc mediates AβO toxicity through mGluR5, Fyn kinase, and NMDARs. Downstream consequences of the pathway include calcium dyshomeostasis, tau hyperphosphorylation, and synaptic dysfunction and loss. Reprinted from “Fyn kinase inhibition as a novel therapy for Alzheimer’s disease” by Nygaard HB, van Dyck CH, and Strittmater SM. This was published in Alzheimers Res Ther, 2014, 6(1): 8, under the terms of the Creative Commons Attribution License (CC BY) [227].](https://figures.cochat.ai/paper-figures/f727ef34b3b345d8b849289bdb182350/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-6.jpg)
![Fig.7 AβOs induce membrane re-distribution of NKAα3 subunit resulting its downregulation and excessive Ca++ buildup. A hypothesized early event in AβO-induced neuronal damage is binding to NKAα3 on neuronal membranes, causing restructuring of the NKAα3 docking station into toxic clusters of membrane proteins. Ultimately, this results in downregulation of NKAα3 on the neuronal surface and buildup of toxic Ca++. Adapted and reprinted from “Alzheimer’s Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station” by DiChiara T, DiNunno N, Clark J, Bu RL, Cline EN, Rollins MG, Gong Y, Brody DL, Sligar SG, Velasco PT, Viola KL, and Klein WL. This was published in Yale J Biol Med, 2017, 90(1): 45-61, under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/ [199].](https://figures.cochat.ai/paper-figures/bd05d1a512054c909e16e461e4020c7c/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-7.jpg)
![Fig.8 A cumulative hypothesis for the development of sporadic AD. From De Felice, sporadic AD is hypothesized to be the result of the cumulative impact over a life-time of injuries to the brain and peripheral organs that results in increased AβO levels. Reprinted from “Alzheimer’s disease and insulin resistance: translating basic science into clinical applications” by De Felice FG. This was published in JClin Invest, 2013, 123(2): 531-539, under Free access [322].](https://figures.cochat.ai/paper-figures/24020b5bf03e43718e18004cdfcd4325/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-8.jpg)
![Fig.9 Putative therapeutic targets of the AβO pathogenic cascade. Including: 1) AβOs themselves; 2) AβO receptors; 3) signaling pathways; or 4) downstream effectors such as tau. Reprinted with permission of PNAS from “Toward a unified therapeutics approach targeting putative amyloid-beta oligomer receptors” by Overk CR and Masliah E. This was published in Proc Natl Acad Sci U S A, 2014, 111(38): 13680-13681 [392].](https://figures.cochat.ai/paper-figures/fd1348f91c8947ff93496ee3a5d93873/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-9.jpg)
![Fig.10 Mechanisms of Aβ-targeting phase III drugs in AD clinical trials. Drugs inhibiting AβO formation (A) or downstream consequences of toxic AβOs (B). Reprinted from “Alzheimer’s disease drug development pipeline: 2017” by Cummings J, Garam L, Mortsdorf T, Ritter A, and Zhong K. This was published in Alzheimers Dementia (N Y), 2017, 3(3): 367-384 [393], under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/) [393].](https://figures.cochat.ai/paper-figures/3fe1a59ed5324adab364ba96901a832d/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-10.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Soluble Aβ oligomers are the primary neurotoxic substances,131–133”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [131]
The cited source says what the claim attributes to it.
In the citing paper
“Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“The Aβ oligomer hypothesis, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers rather than amyloid plaques as key players in AD pathogenesis [4,5,6,7].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of Aβ [4,5,6,7,18].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
In the citing paper
“The alternative “Aβ oligomer hypothesis”, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers (AβO)s rather than amyloid plaques as key players in AD pathogenesis [79,80,81].”
From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedLarson, M., Sherman, M. A., Amar, F., Nuvolone, M., Schneider, J. A., Bennett, D. A., Aguzzi, A., & Lesné, S. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1858-12.2012 · Cited by 277
RetractedRETRACTED: Cognitive effects of cell-derived and synthetically derived Aβ oligomers
Reed, M. N., Hofmeister, J. J., Jungbauer, L., Welzel, A. T., Yu, C., Sherman, M. A., Lesné, S., LaDu, M. J., Walsh, D. M., Ashe, K. H., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.11.007 · Cited by 131
RetractedAmar, F., Sherman, M. A., Rush, T., Larson, M., Boyle, G., Chang, L., Götz, J., Buisson, A., & Lesné, S. E. (2017) · Science Signaling · doi:10.1126/scisignal.aal2021 · Cited by 112
RetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 6×
“dence that AD is a transmissible prion-like disease [5], experimental data support the idea that A Os may spread from cell-to-cell and brain region-toregion in a prion-like manner.”
BackgroundInfluentialAmyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Research works printed but not linked: 4
- Meilandt, 2017, Characterization of the selective in vivo and in vitro binding properties of crenezumab: Insights into crenezumab’s unique mechanism of action, J Prev Alzheimers Dis, 4, 293
- Schneider, 2017, The anti-AB oligomer drug CT1812 for Alzheimer’s: Phase 1B/2A safety trial outcomes, J Prev Alzheimers Dis, 4, 317
- Catalano, 2017, Biomarker outcomes from the phase 1b/2a safety trial of the anti-AB oligomer drug CT1812 in Alzheimer’s patients, J Prev Alzheimers Dis, 4, 401
- Leslie, 2017, Phase II study to assess safety and target engagement of AMX0035, a novel combination therapy, in Alzheimer’s disease, Neurotherapeutics, 14, 825
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“121 – 124 Moreover, other genetic risk factors, 125,126 cardiovascular health issues (such as diabetes, hypercholesterolemia), and lifestyle factors (such as diet and sleep) 127 have also been extensively studied in recent years for their relationship with A β metabolism in SAD.”
BackgroundAlzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689
Half a century of amyloids: past, present and future
Ke, P. C., Zhou, R., Serpell, L. C., Riek, R., Knowles, T. P. J., Lashuel, H. A., Gazit, E., Hamley, I. W., Davis, T. P., Fändrich, M., et al. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00199a · Cited by 568
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
α-synuclein in the pathophysiology of Alzheimer’s disease
Twohig, D., & Nielsen, H. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0320-x · Cited by 374
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
the Synaptic Health Endpoints Working Group, Colom-Cadena, M., Spires-Jones, T., Zetterberg, H., Blennow, K., Caggiano, A., DeKosky, S. T., Fillit, H., Harrison, J. E., Schneider, L. S., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00588-4 · Cited by 328
Sengupta, U., & Kayed, R. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102270 · Cited by 293
Chen, X.-Q., & Mobley, W. C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00659 · Cited by 289
The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis
Tolar, M., Abushakra, S., & Sabbagh, M. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.09.075 · Cited by 275
“When Ab oligomers were isolated from the brains of patients with AD [13,14], their levels were shown to closely correlate with the onset of disease progression and the severity of clinical symptoms [15–17].”
BackgroundProteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery
Bai, B., Vanderwall, D., Li, Y., Wang, X., Poudel, S., Wang, H., Dey, K. K., Chen, P.-C., Yang, K., & Peng, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00474-z · Cited by 257
Tolar, M., Hey, J., Power, A., & Abushakra, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126355 · Cited by 243
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology
Rahman, M. M., & Lendel, C. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00465-0 · Cited by 239
Jamwal, S., Blackburn, J. K., & Elsworth, J. D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107705 · Cited by 236
Neuronal cell death mechanisms in Alzheimer’s disease: An insight
Goel, P., Chakrabarti, S., Goel, K., Bhutani, K., Chopra, T., & Bali, S. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.937133 · Cited by 234
Morris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212
Li, Y., Zhang, J., Wan, J., Liu, A., & Sun, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110887 · Cited by 197
Understanding the Amyloid Hypothesis in Alzheimer’s Disease
Paroni, G., Bisceglia, P., & Seripa, D. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180802 · Cited by 187
The Role of Glymphatic System in Alzheimer’s and Parkinson’s Disease Pathogenesis
Buccellato, F. R., D’Anca, M., Serpente, M., Arighi, A., & Galimberti, D. (2022) · Biomedicines · doi:10.3390/biomedicines10092261 · Cited by 169
Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Vaz, M., Silva, V., Monteiro, C., & Silvestre, S. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s325026 · Cited by 183
Buccellato, F. R., D’Anca, M., Fenoglio, C., Scarpini, E., & Galimberti, D. (2021) · Antioxidants · doi:10.3390/antiox10091353 · Cited by 179
Simulation Studies of Amyloidogenic Polypeptides and Their Aggregates
Ilie, I. M., & Caflisch, A. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00731 · Cited by 178
Chen, X.-Q., & Mobley, W. C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00446 · Cited by 175
Fluid Biomarkers for Synaptic Dysfunction and Loss
Camporesi, E., Nilsson, J., Brinkmalm, A., Becker, B., Ashton, N. J., Blennow, K., & Zetterberg, H. (2020) · Biomarker Insights · doi:10.1177/1177271920950319 · Cited by 165
Yu, S. P., Jiang, M. Q., Shim, S. S., Pourkhodadad, S., & Wei, L. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00636-1 · Cited by 190
Harris, S. S., Wolf, F., De Strooper, B., & Busche, M. A. (2020) · Neuron · doi:10.1016/j.neuron.2020.06.005 · Cited by 161
Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
Plotkin, S. S., & Cashman, N. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105010 · Cited by 155
Kwak, S. S., Washicosky, K. J., Brand, E., von Maydell, D., Aronson, J., Kim, S., Capen, D. E., Cetinbas, M., Sadreyev, R., Ning, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15120-3 · Cited by 151
Schützmann, M. P., Hasecke, F., Bachmann, S., Zielinski, M., Hänsch, S., Schröder, G. F., Zempel, H., & Hoyer, W. (2021) · Nature Communications · doi:10.1038/s41467-021-24900-4 · Cited by 143
Galectin-3 promotes Aβ oligomerization and Aβ toxicity in a mouse model of Alzheimer’s disease
Tao, C.-C., Cheng, K.-M., Ma, Y.-L., Hsu, W.-L., Chen, Y.-C., Fuh, J.-L., Lee, W.-J., Chao, C.-C., & Lee, E. H. Y. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0348-z · Cited by 138
Rinauro, D. J., Chiti, F., Vendruscolo, M., & Limbocker, R. A. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00651-2 · Cited by 120
Altered succinylation of mitochondrial proteins, APP and tau in Alzheimer’s disease
Yang, Y., Tapias, V., Acosta, D., Xu, H., Chen, H., Bhawal, R., Anderson, E. T., Ivanova, E., Lin, H., Sagdullaev, B. T., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27572-2 · Cited by 118
Self-citationTransgenic Mouse Models of Alzheimer’s Disease: An Integrative Analysis
Sanchez-Varo, R., Mejias-Ortega, M., Fernandez-Valenzuela, J. J., Nuñez-Diaz, C., Caceres-Palomo, L., Vegas-Gomez, L., Sanchez-Mejias, E., Trujillo-Estrada, L., Garcia-Leon, J. A., Moreno-Gonzalez, I., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105404 · Cited by 129
Gomes, L. A., Hipp, S. A., Rijal Upadhaya, A., Balakrishnan, K., Ospitalieri, S., Koper, M. J., Largo-Barrientos, P., Uytterhoeven, V., Reichwald, J., Rabe, S., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02053-5 · Cited by 125
The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation
Castellani, R. J., Plascencia‐Villa, G., & Perry, G. L. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0231-z · Cited by 139
Exploring ER stress response in cellular aging and neuroinflammation in Alzheimer's disease
Uddin, M. S., Yu, W. S., & Lim, L. W. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101417 · Cited by 135
Welikovitch, L. A., Do Carmo, S., Maglóczky, Z., Malcolm, J. C., Lőke, J., Klein, W. L., Freund, T., & Cuello, A. C. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914593117 · Cited by 116
Self-citationPenke, B., Szűcs, M., & Bogár, F. (2020) · Molecules · doi:10.3390/molecules25071659 · Cited by 114
Sanders, O., & Rajagopal, L. (2020) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-200191 · Cited by 113
Phosphorylation Signaling in APP Processing in Alzheimer’s Disease
Zhang, T., Chen, D., & Lee, T. H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010209 · Cited by 112
Tau Protein Squired by Molecular Chaperones During Alzheimer’s Disease
Gorantla, N. V., & Chinnathambi, S. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1174-3 · Cited by 119
Fišar, Z. (2022) · Biomolecules · doi:10.3390/biom12111676 · Cited by 120
The Beta Amyloid Dysfunction (BAD) Hypothesis for Alzheimer’s Disease
Hillen, H. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01154 · Cited by 106
Mullane, K., & Williams, M. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113945 · Cited by 105
Aggregation and structure of amyloid β-protein
Ono, K., & Watanabe-Nakayama, T. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105208 · Cited by 95
Gouveia, F., Camins, A., Ettcheto, M., Bicker, J., Falcão, A. C., Cruz, M. T., & Fortuna, A. C. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101612 · Cited by 104
Walker, L. C. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-3025 · Cited by 171
Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813900 · Cited by 94
TREM2 in Alzheimer’s Disease: Microglial Survival and Energy Metabolism
Zheng, H., Cheng, B., Li, Y., Li, X., Chen, X., & Zhang, Y.-W. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00395 · Cited by 94
Ono, K., & Tsuji, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030952 · Cited by 92
Yang, T., Dang, Y., Ostaszewski, B., Mengel, D., Steffen, V., Rabe, C., Bittner, T., Walsh, D. M., & Selkoe, D. J. (2019) · Annals of Neurology · doi:10.1002/ana.25513 · Cited by 91
“Converging lines of evidence suggest that soluble, diffusible Aβ oligomers are a key pathogenic factor in AD and that reducing cerebral oAβ levels could have disease-modifying benefit in patients with early stage disease.(1,2) However, measurement of Aβ oligomers is challenging due to their hydrophobicity and very low…”
The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer’s disease
Su, Q., Guo, J.-H., Zhang, Y.-L., Wang, J., & Zhang, Z.-N. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335829 · Cited by 91
“…demonstrated to blockade long-term potentiation, drive synaptic dysfunction, spread oxidative stress and neuroinflammation, facilitate tau phosphorylation, deteriorate neuronal health, and finally lead to neuronal death (Kayed and Lasagna-Reeves, 2013; Viola and Klein, 2015; Cline et al., 2018).”
BackgroundHyperactivity Induced by Soluble Amyloid-β Oligomers in the Early Stages of Alzheimer's Disease
Hector, A., & Brouillette, J. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.600084 · Cited by 87
García-González, L., Pilat, D., Baranger, K., & Rivera, S. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00244 · Cited by 88
“…events triggered by its accumulation, including stimulation of Tau hyperphosphorylation and subsequent formation of neurofibrillary tangles (NFTs), promotion of inflammation and also synaptic dysfunctions (Benilova et al., 2012; Mucke and Selkoe, 2012; Selkoe and Hardy, 2016; Cline et al., 2018).”
BackgroundBrain injury-induced dysfunction of the blood brain barrier as a risk for dementia
Abrahamson, E. E., & Ikonomovic, M. D. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113257 · Cited by 86
Neuropathological assessment of the Alzheimer spectrum
Jellinger, K. A. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02232-9 · Cited by 89
de Vries, L. E., Huitinga, I., Kessels, H. W., Swaab, D. F., & Verhaagen, J. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00719-7 · Cited by 72
The role of APOE in transgenic mouse models of AD
Balu, D., Karstens, A. J., Loukenas, E., Maldonado Weng, J., York, J. M., Valencia-Olvera, A. C., & LaDu, M. J. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134285 · Cited by 81
Inhibition of the Self-Assembly of Aβ and of Tau by Polyphenols: Mechanistic Studies
Zheng, Q., Kebede, M. T., Kemeh, M. M., Islam, S., Lee, B., Bleck, S. D., Wurfl, L. A., & Lazo, N. D. (2019) · Molecules · doi:10.3390/molecules24122316 · Cited by 80
Neuropathological Mechanisms Associated with Pesticides in Alzheimer’s Disease
Tang, B. L. (2020) · Toxics · doi:10.3390/toxics8020021 · Cited by 85
Interactions of α-synuclein oligomers with lipid membranes
Musteikytė, G., Jayaram, A. K., Xu, C. K., Vendruscolo, M., Krainer, G., & Knowles, T. P. J. (2020) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2020.183536 · Cited by 88
Salvadores, N., Moreno‐González, I., Gamez, N., Quiroz, G., Vegas‐Gomez, L., Escandón, M., Jiménez, S., Vitórica, J., Gutiérrez, A., Soto, C. A., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01332-9 · Cited by 92
Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer’s Disease
Pradeepkiran, J. A., Baig, J., Islam, M. A., Kshirsagar, S., & Reddy, P. H. (2024) · Aging and Disease · doi:10.14336/ad.2024.0286 · Cited by 102
Quintela-López, T., Ortiz-Sanz, C., Serrano-Regal, M. P., Gaminde-Blasco, A., Valero, J., Baleriola, J., Sánchez-Gómez, M. V., Matute, C., & Alberdi, E. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1636-8 · Cited by 80
Early diagnosis and treatment of Alzheimer’s disease by targeting toxic soluble Aβ oligomers
Habashi, M., Vutla, S., Tripathi, K. K., Senapati, S., Chauhan, P. S., Haviv‐Chesner, A., Richman, M., Mohand, S.-A., Dumulon‐Perreault, V., Mulamreddy, R., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2210766119 · Cited by 88
Aβ-oligomers: A potential therapeutic target for Alzheimer's disease
Ghosh, S., Ali, R., & Verma, S. K. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.124231 · Cited by 87
Merlo, S., Spampinato, S. F., & Sortino, M. A. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13050 · Cited by 85
Neurotoxic β-amyloid oligomers cause mitochondrial dysfunction—the trigger for PANoptosis in neurons
Meng, X., Song, Q., Liu, Z., Liu, X., Wang, Y., & Liu, J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1400544 · Cited by 88
Amyloid beta acts synergistically as a pro-inflammatory cytokine
LaRocca, T. J., Cavalier, A. N., Roberts, C. M., Lemieux, M. R., Ramesh, P., Garcia, M. A., & Link, C. D. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105493 · Cited by 78
Disorder-to-order transition of the amyloid-β peptide upon lipid binding
Fatafta, H., Kav, B., Bundschuh, B. F., Loschwitz, J., & Strodel, B. (2021) · Biophysical Chemistry · doi:10.1016/j.bpc.2021.106700 · Cited by 79
Melatonin: A potential nighttime guardian against Alzheimer’s
Zhang, Z., Xue, P., Bendlin, B. B., Zetterberg, H., Felice, F. G. D., Tan, X. W., & Benedict, C. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02691-6 · Cited by 82
Johnson, E. C. B., Ho, K., Yu, G.-Q., Das, M., Sanchez, P. E., Djukic, B., Lopez, I., Yu, X., Gill, M., Zhang, W., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00393-5 · Cited by 73
Lewandowski, C. T., Maldonado Weng, J., & LaDu, M. J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104811 · Cited by 72
Viles, J. H. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202215785 · Cited by 81
Granzotto, A., Vissel, B., & Sensi, S. L. (2024) · eLife · doi:10.7554/elife.90633 · Cited by 71
An Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity?
Sciaccaluga, M., Megaro, A., Bellomo, G., Ruffolo, G., Romoli, M., Palma, E., & Costa, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115991 · Cited by 70
Rangan, P., Lobo, F., Parrella, E., Rochette, N. C., Morselli, M., Stephen, T., Cremonini, A. L., Tagliafico, L., Persia, A., Caffa, I., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111417 · Cited by 79
“Amyloid‐beta accumulation cycle” as a prevention and/or therapy target for Alzheimer's disease
Rao, C. V., Asch, A. S., Carr, D. J. J., & Yamada, H. Y. (2020) · Aging Cell · doi:10.1111/acel.13109 · Cited by 71
Passive immunotherapy for Alzheimer's disease
Guo, X., Li, Y., Zhang, D., & Zhao, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102192 · Cited by 78
Ding, Y., Zhao, J., Zhang, X., Wang, S., Viola, K. L., Chow, F. E., Zhang, Y., Lippa, C., Klein, W. L., & Gong, Y. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01140 · Cited by 65
Self-citationBlood Amyloid-β Oligomerization as a Biomarker of Alzheimer’s Disease: A Blinded Validation Study
Youn, Y. C., Lee, B. S., Kim, G. J., Ryu, J. S., Lim, K., Lee, R., Suh, J., Park, Y. H., Pyun, J., Ryu, N., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200061 · Cited by 69
Progress toward Alzheimer's disease treatment: Leveraging the Achilles' heel of Aβ oligomers?
Fantini, J., Chahinian, H., & Yahi, N. (2020) · Protein Science · doi:10.1002/pro.3906 · Cited by 64
Amyloid-β peptide 37, 38 and 40 individually and cooperatively inhibit amyloid-β 42 aggregation
Braun, G. A., Dear, A. J., Sanagavarapu, K., Zetterberg, H., & Linse, S. S. (2022) · Chemical Science · doi:10.1039/d1sc02990h · Cited by 75
The amyloid precursor protein: a converging point in Alzheimer’s disease
Delport, A., & Hewer, R. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02863-x · Cited by 67
Protein aggregation and its affecting mechanisms in neurodegenerative diseases
Wu, J., Wu, J., Chen, T., Cai, J., & Ren, R. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105880 · Cited by 69
Mitochondrial Permeability Transition: A Pore Intertwines Brain Aging and Alzheimer’s Disease
Jia, K., & Du, H. (2021) · Cells · doi:10.3390/cells10030649 · Cited by 65
Wu, J., Blum, T. B., Farrell, D. P., DiMaio, F., Abrahams, J. P., & Luo, J. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202104497 · Cited by 61
Malkov, A., Popova, I., Ivanov, A., Jang, S.-S., Yoon, S. Y., Osypov, A., Huang, Y., Zilberter, Y., & Zilberter, M. (2021) · Communications Biology · doi:10.1038/s42003-021-02551-x · Cited by 59
Shea, D. W., Colasurdo, E. A., Smith, A. S. T., Paschall, C. J., Jayadev, S., Keene, C. D., Galasko, D. R., Ko, A. L., Li, G., Peskind, E. R., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2213157119 · Cited by 65
Anti-herpetic tau preserves neurons via the cGAS-STING-TBK1 pathway in Alzheimer’s disease
Hyde, V. R., Zhou, C., y Fernández, J. R. M., Chatterjee, K., Ramakrishna, P., Lin, A., Fisher, G. W., Celiker, O. T., Caldwell, J., Bender, O., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2024.115109 · Cited by 66
Protein Solubility Predictions Using the CamSol Method in the Study of Protein Homeostasis
Sormanni, P., & Vendruscolo, M. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033845 · Cited by 64
The AppNL-G-F mouse retina is a site for preclinical Alzheimer’s disease diagnosis and research
Vandenabeele, M., Veys, L., Lemmens, S., Hadoux, X., Gelders, G., Masin, L., Serneels, L., Theunis, J., Saito, T., Saido, T. C., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01102-5 · Cited by 64
Tomiyama, T., & Shimada, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041413 · Cited by 65
Vaccination against β-Amyloid as a Strategy for the Prevention of Alzheimer’s Disease
Mantile, F., & Prisco, A. (2020) · Biology · doi:10.3390/biology9120425 · Cited by 56
Role of GPCR signaling and calcium dysregulation in Alzheimer's disease
Sushma, & Mondal, A. C. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.103414 · Cited by 61
Vandendriessche, C., Balusu, S., Van Cauwenberghe, C., Brkic, M., Pauwels, M., Plehiers, N., Bruggeman, A., Dujardin, P., Van Imschoot, G., Van Wonterghem, E., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01245-z · Cited by 56
Liu, X.-G., Zhang, L., Lu, S., Liu, D.-Q., Zhang, L.-X., Yu, X.-L., & Liu, R.-T. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s240953 · Cited by 55
Ortiz-Sanz, C., Balantzategi, U., Quintela‐López, T., Ruiz, A., Luchena, C., Zuazo-Ibarra, J., Capetillo‐Zarate, E., Matute, C., Zugaza, J. L., & Alberdi, E. M. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04687-y · Cited by 63
Amyloid oligomers as on-pathway precursors or off-pathway competitors of fibrils
Muschol, M., & Hoyer, W. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1120416 · Cited by 59
The Role of Lipid Environment in Ganglioside GM1-Induced Amyloid β Aggregation
Rudajev, V., & Novotný, J. (2020) · Membranes · doi:10.3390/membranes10090226 · Cited by 61
Bigi, A., Cascella, R., Chiti, F., & Cecchi, C. (2022) · BioEssays · doi:10.1002/bies.202200086 · Cited by 61
Metadata
- Authors
- Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L.
- Affiliations
- Northwestern University (US)
- Department of Neurobiology, Cognitive Neurology and Alzheimer’s Disease Center, International Institute for Nanotechnology, and Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, USA
- Corresponding author
- Klein, William L.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-06-12
- Volume
- 64
- Issue
- s1
- Pages
- S567-S610
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC6004937
- OpenAlex
- W2809078375
- Cited by
- 870
- References
- 457
- Citations by year
- 2026: 72 · 2025: 109 · 2024: 99 · 2023: 133 · 2022: 123 · 2021: 123 · 2020: 119 · 2019: 74 · 2018: 17
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (R41AG054337, T32AG020506)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta oligomers, Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Humans, Models, Neurological, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.